Copolymer, antibody-copolymer conjugate preparation kit, antibody-copolymer conjugate, method for concentrating antigen, and method for detecting antigen

A temperature-responsive copolymer forms an antibody-copolymer conjugate to concentrate antigens, addressing the false positive issue in COVID-19 diagnosis by enhancing test sensitivity and accuracy.

JP7580154B2Active Publication Date: 2024-11-11NAT INST FOR MATERIALS SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023514514
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-04-12
Filing Date
2022-03-07
Publication Date
2024-11-11
Estimated Expiration
2042-03-07

AI Technical Summary

Technical Problem

The high false positive rate in COVID-19 diagnosis due to the small amount of virus, antibodies, and/or antigens in the specimen necessitates a method for easily concentrating the test target and improving test sensitivity.

Method used

A copolymer containing specific repeating units with temperature responsiveness and a click reaction site is used to form an antibody-copolymer conjugate, which concentrates antigens by forming a complex and precipitating at specific temperatures, enabling antigen detection.

Benefits of technology

The method effectively concentrates antigens, reducing false positives and enhancing the sensitivity of COVID-19 testing by immobilizing antibodies, thereby improving diagnostic accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580154000032
    Figure 0007580154000032
  • Figure 0007580154000033
    Figure 0007580154000033
  • Figure 0007580154000034
    Figure 0007580154000034
Patent Text Reader

Abstract

A copolymer according to the present invention includes a unit 1 which is a repeating unit represented by formula 1, and a unit 2 which is a repeating unit represented by formula 2, and can be used to concentrate an antigen by immobilizing an antibody.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a copolymer, an antibody-copolymer conjugate preparation kit, an antibody-copolymer conjugate, a method for concentrating an antigen, and a method for detecting an antigen. [Background technology]

[0002] There are known "temperature-responsive polymers" that undergo a phase transition and change their physical properties in response to changes in the temperature of the solution. Patent Document 1 describes a polymer of an "isopropylacrylamide derivative having an azide group or an alkyne group" as such a temperature-responsive polymer. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] JP 2012-201634 A Summary of the Invention Problems to be Solved by the Invention

[0004] In diagnosing COVID-19 (SARS-CoV-2), a high false positive rate is an issue due to the low amounts of virus, antibodies, and / or antigens (especially antigens) in samples, and there is a demand for a method to easily concentrate the test targets and improve the test sensitivity.

[0005] Therefore, an objective of the present invention is to provide a copolymer that can be used to concentrate an antigen by immobilizing an antibody. Another objective of the present invention is to provide an antibody-copolymer conjugate production kit, an antibody-copolymer conjugate, a method for concentrating an antigen, and a method for detecting an antigen. [Means for solving the problem]

[0006] As a result of extensive investigations aimed at achieving the above object, the present inventors have found that the above object can be achieved by the following configuration.

[0007] [1] A copolymer containing unit 1 described below and unit 2 described below. [2] The copolymer according to [1], wherein the content of the unit 2 is 1.0 to 30.0 mol % when all repeating units are taken as 100 mol %. [3] The copolymer according to [1] or [2], wherein the unit 2 is a unit 3 represented by the formula 3 described below, or a unit 4 represented by the formula 4 described below. [4] The copolymer according to any one of [1] to [3], further comprising a repeating unit represented by formula 5 described below. [5] The copolymer according to any one of [1] to [4], wherein the content of the unit 2 is 5 to 30 mol % or less, when all repeating units are taken as 100 mol %. [6] The copolymer according to any one of [1] to [5], having a number average molecular weight of 5,000 to 50,000. [7] A kit for producing an antibody-copolymer conjugate, comprising the copolymer according to any one of [1] to [6] and a linker represented by the formula 4 described below. [8] An antibody-copolymer conjugate having unit 1 described below and unit 7 described below. [9] The antibody-copolymer conjugate according to [8], wherein the Ab in the antibody-copolymer conjugate is an anti-SARS-CoV-2 antibody.

[10] A method for concentrating an antigen, comprising: preparing a mixed solution A containing the antibody-copolymer conjugate according to [8] or [9] and an antigen corresponding to the antibody, forming a complex between the antibody-copolymer conjugate and the antigen, and heating the mixed solution A to 20 to 40°C to precipitate the complex.

[11] The method for concentrating an antigen according to

[10] , further comprising: preparing an antibody-linker conjugate by binding a linker represented by formula 4 described below to the antibody via an amide bond derived from an amino group of the antibody; preparing a mixture B containing the antibody-linker conjugate and a copolymer comprising unit 1 described below and unit 2 described below; and reacting an azide group of the antibody-linker conjugate with an alkynylene group of the copolymer in the mixture B to bind them, thereby producing the antibody-copolymer conjugate.

[12] The method for concentrating an antigen described in

[10] or

[11] , wherein the antibody is an anti-SARS-CoV-2 antibody.

[13] The method for concentrating an antigen described in

[12] , wherein the antigen is a SARS-CoV-2 protein.

[14] The method for concentrating an antigen according to

[11] , wherein a molar ratio of the content of the copolymer to the content of the antibody contained in the antibody-linker complex in the mixed solution B is 0.5 to 30.

[15] A method for detecting an antigen, comprising concentrating an antigen by the method for concentrating an antigen according to any one of

[10] to

[14] , and detecting the concentrated antigen. Effect of the Invention

[0008] According to the present invention, a copolymer that can be used for concentrating an antigen by immobilizing an antibody can be provided. In addition, according to the present invention, an antibody-copolymer conjugate preparation kit, an antibody-copolymer conjugate, a method for concentrating an antigen, and a method for detecting an antigen can also be provided. [Brief description of the drawings]

[0009] [Figure 1] The synthesized HIPAAm was visualized by thin layer chromatography (TLC). [Diagram 2] This is the result of 1H NMR analysis of HIPAAm monomer. [Diagram 3] 1H NMR analysis result of P(NIPAAm-co-HIPAAm). [Figure 4] 1 shows the results of 1H NMR analysis of specific copolymer (I). [Diagram 5] This is the result of measuring the LCST (Lower critical solution temperature) of the synthesized P(NIPAAm-co-HIPAAm). [Figure 6] 1 shows the results of LCST measurement of the synthesized specific copolymer (I). [Figure 7] 1 shows the results of measuring the LCST of a conjugate of an antibody and a specific copolymer (I). [Figure 8] The amount of azide (EG)4-NHS introduced per Covid-19 antibody was measured using fluorescamine. [Figure 9] 1 shows the results of evaluation of the click reaction between an antibody and synthetic polymers at different concentrations by SDS-PAGE. [Figure 10] FIG. 1 shows the enrichment rate of COVID-19 recombinant proteins at different concentrations of antibody conjugates. [Figure 11] Evaluation of the concentrating effect of a temperature-responsive polymer on COVID-19 antibodies using lateral flow immunoassay (LFIA). [Figure 12] Evaluation of the concentrating effect of a temperature-responsive polymer on COVID-19 antibodies using lateral flow immunoassay (LFIA). [Figure 13] 1 shows the results of measuring the LCST of the synthesized copolymer (II). [Figure 14] This is the result of measuring the amount of azide (EG)4-NHS introduced per Covid-19 antibody (antibody for capturing S protein) using fluorescamine. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The present invention will be described in detail below. The following description of the components may be based on a representative embodiment of the present invention, but the present invention is not limited to such an embodiment. In this specification, a numerical range expressed using "to" means a range that includes the numerical values ​​before and after "to" as the lower and upper limits.

[0011] [Copolymer] The copolymer according to the embodiment of the present invention (hereinafter also referred to as "specific copolymer") is a copolymer containing a repeating unit (unit 1) represented by the following formula 1 and a repeating unit (unit 2) represented by the following formula 2.

[0012] [ka]

[0013] (Unit 1) A polymer constituted solely by the unit 1 exhibits temperature responsiveness to water with a LCST (Lower Critical Solution Temperature) of 32° C. By including the unit 1, the specific copolymer has temperature responsiveness.

[0014] The content of unit 1 contained in the specific copolymer is not particularly limited, and is typically preferably 1 to 99 mol% when the total repeating units are taken as 100 mol%. In particular, from the viewpoint of the specific copolymer having more sensitive temperature responsiveness and / or the ease of controlling the LCST to a temperature range suitable for concentrating antigens (specifically, the LCST is likely to be room temperature to about 40°C), the content of unit 1 in the specific copolymer is preferably more than 50 mol%, more preferably 60 mol% or more, preferably 97 mol% or less, and more preferably 90 mol% or less.

[0015] In formula 1, X 1 represents a hydrogen atom, or a linear or branched alkyl group having 1 to 6 carbon atoms. From the viewpoint of providing the specific copolymer with more sensitive temperature responsiveness, a hydrogen atom or a linear alkyl group having 1 to 4 carbon atoms is preferred, and a hydrogen atom or a methyl group is more preferred.

[0016] Although not particularly limited, unit 1 is preferably a unit based on a monomer represented by the following formula 1'.

[0017] [ka]

[0018] In formula 1′, X 1 is X in Eq. 1 The monomer represented by formula 1' may be synthesized by a known method, for example, a method described in the examples below, or a commercially available product may be used.

[0019] (Unit 2) The specific copolymer has a unit 2 represented by formula 2. The unit 2 has one site (click reaction site) containing a cyclic alkyne (alkynylene group) per repeating unit, and can be bonded to an azide group of a linker described later by a click reaction to easily form a complex. For example, if a linker and a protein (such as an antibody) are bonded in advance, the protein can be immobilized to the specific copolymer via the linker. That is, an antibody-copolymer conjugate can be produced. The conjugates produced undergo aggregation and precipitation at or above the LCST due to the temperature responsiveness of the specific copolymer, which can be used to concentrate antigens corresponding to antibodies.

[0020] The content of unit 2 in the specific copolymer is not particularly limited, but is typically preferably 1 to 99 mol % when the total amount of repeating units in the specific copolymer is taken as 100 mol %. Among these, from the viewpoint of lowering the LCST and enabling more sensitive detection of the antigen after concentration, the concentration is preferably 1 mol % or more, more preferably 2 mol % or more, and even more preferably 5 mol % or more, and is preferably 30 mol % or less, and more preferably 20 mol % or less.

[0021] Unit 2 typically has a higher hydrophobicity than other repeating units, and by increasing the content of unit 2, the LCST can be made lower. Furthermore, the greater the content of unit 2, the easier it is to introduce the antibody. On the other hand, in consideration of applications in which the solution is concentrated by heating to 20 to 40° C., the content of unit 2 is preferably 1 mol % or more, more preferably 2 mol % or more, even more preferably 5 mol % or more, particularly preferably 10 mol %, preferably 30 mol % or less, more preferably 20 mol % or less.

[0022] [ka]

[0023] In formula 2, X 2 represents a hydrogen atom, or a linear or branched alkyl group having 1 to 6 carbon atoms. From the viewpoint of providing the specific copolymer with more sensitive temperature responsiveness, a hydrogen atom or a linear alkyl group having 1 to 4 carbon atoms is preferred, and a hydrogen atom or a methyl group is more preferred.

[0024] In formula 2, L 2 represents a divalent group. 2 is not particularly limited, and may be -O-, -S-, -C(O)-, -C(O)O-, -OC(O)O-, -NR A -(R A is a hydrogen atom or a monovalent substituent), a linear, branched, or cyclic aliphatic hydrocarbon group having 1 to 20 carbon atoms, a monocyclic or fused ring aromatic hydrocarbon group having 6 to 20 carbon atoms, and a combination thereof are preferred. Among these, from the viewpoint of obtaining a copolymer having a more excellent effect of the present invention, -O-, -C(O)-, -NR A More preferred is one group selected from the group consisting of -, a linear alkylene group having 1 to 10 carbon atoms, and a combination thereof, and -O-, -C(O)-, and -NR A At least one group selected from the group consisting of - is more preferred, and -0-, -C(O)-, or -NH- is particularly preferred.

[0025] In formula 2, R 1 is a hydrogen atom, a halogen atom, -OR 5 , -NO2, -CN, -S(O)2R 5 , an alkyl group having 1 to 24 carbon atoms, an alkenyl group having 2 to 24 carbon atoms, and a (hetero)aryl group having 6 to 24 carbon atoms; 1 may be bonded to each other to form a ring, R 5 is selected from the group consisting of hydrogen, halogen atoms, alkyl groups having 1 to 24 carbon atoms, and (hetero)aryl groups having 6 to 24 carbon atoms; Z is C(R 1 )2, O, S, and NR 1 a′ is an integer from 0 to 8, a″ is an integer from 0 to 8, and the sum of a′ and a″ is less than 10. 1 may be the same or different from each other.

[0026] Unit 2 is L 2 When the bonding site with is represented by "*", it is preferable to have, for example, a structure (click reaction site) represented by the following formula C. In other words, it is preferable to have a structure represented by the following formula C as a bonding site (monovalent group) at the position of "*" after the wavy line represented by the following formula.

[0027] [ka]

[0028] [ka]

[0029] From the viewpoint of obtaining a copolymer having a more excellent effect of the present invention, the unit 2 is preferably at least one type selected from the group consisting of units represented by the following formulas. In the following formula, L 21 represents a divalent group, and L in formula 2 2 The same applies to the preferred embodiments. 2is X in Eq. 2 The same applies to the preferred embodiments.

[0030] [ka]

[0031] Among these, from the viewpoint of obtaining a copolymer having more excellent effects of the present invention, the unit 2 is preferably the unit 3 or the unit 4 represented by the following formula 3 or 4.

[0032] [ka]

[0033] In formula 3 and formula 4, X 2 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms; 3 -O-, -S-, and -NR B -, and R B represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, n represents an integer of 1 to 10, and in formula 4, L 2 represents a divalent group, and a preferred embodiment is 2 The same applies to the divalent group represented by the formula:

[0034] The method for synthesizing unit 2 is not particularly limited, and any known synthesis method can be used. However, a method for obtaining unit 2 by binding a precursor compound to unit 2' represented by the following formula 2' is preferred, since it allows unit 2 to be obtained more easily.

[0035] [ka]

[0036] In formula 2′, R C is a reactive substituent, and specific examples thereof include a hydroxy group, an amino group, a carboxy group, a glycidyl group, a mercapto group, a hydroxysuccinimide ester, and a maleimide group, with a hydroxy group being preferred.

[0037] The precursor compound may be, for example, a compound having a click reaction site and the above R C A compound having a group capable of reacting with the above may be used, and a commercially available product may be used, or a compound synthesized by a known method may be used. In particular, the specific copolymer can be more easily synthesized by using a precursor compound having a structure (click reaction site) represented by the above formula C and a carboxy group.

[0038] For example, when the click reaction site is a difluorinated cyclooctyne, the method described in Schemes 1 and 2 of J. Am. Chem. Soc. 2008, 130, 34, 11486-11493 can be used to synthesize the precursor compound. When the click reaction site is a dibenzoazacyclooctyne, the method described in Scheme 1 of Chemical Communications (2010), 46(1), 97-99 can be used.

[0039] In addition, compounds in which substituents such as amino groups, hydroxy groups, and carboxy groups are added to the click reaction sites BCN (bicyclo[6.1.0]nonyne) and DBCO, as well as compounds in which maleimide and hydroxysuccinimide esters are added, are commercially available, and these can also be used as precursor compounds.

[0040] Among them, the unit 2' is preferably the unit 5 represented by the following formula 5, since the unit 2 can be obtained more easily. In this case, the precursor compound may typically be a precursor compound having a carboxy group and a structure represented by formula C.

[0041] [ka]

[0042] When the specific copolymer is synthesized, if there is unreacted unit 5, in other words, if the specific copolymer contains unit 1, unit 2, and unit 5, the LCST can be adjusted to a higher temperature. Since unit 5 has higher hydrophilicity than other repeating units, the LCST can be adjusted to a higher temperature by increasing the content of unit 5.

[0043] In the above formula 5, X 5 represents a hydrogen atom, or a linear or branched alkyl group having 1 to 6 carbon atoms. From the viewpoint of providing the copolymer with more sensitive temperature responsiveness, a hydrogen atom or a linear alkyl group having 1 to 4 carbon atoms is preferred, and a hydrogen atom or a methyl group is more preferred.

[0044] The content of unit 5 in the specific copolymer is not particularly limited, but is preferably 0 to 15 mol % when the total amount of all repeating units in the specific copolymer is taken as 100 mol %.

[0045] The molecular weight of the specific copolymer is not particularly limited, but typically, the number average molecular weight is preferably 2,000 to 100,000, more preferably 5,000 to 50,000, and even more preferably 10,000 to 30,000. When the number average molecular weight is 5,000 or more, better concentration efficiency is likely to be obtained (in other words, better temperature responsiveness is likely to be obtained), whereas when the number average molecular weight is 50,000 or less, a conjugate with an antibody is likely to be formed, or an antigen-antibody reaction is likely to proceed.

[0046] In particular, in terms of obtaining better concentration efficiency when an antibody-copolymer conjugate prepared from the obtained copolymer is used, the number average molecular weight is preferably not less than 15000, and more preferably not less than 20000. In general, antibodies are often highly hydrophilic, and in such cases, a copolymer having better concentration efficiency is required. When the number average molecular weight of the copolymer is within the above numerical range, a good concentration efficiency is easily obtained. Furthermore, the ratio of the molecular weight of the specific copolymer to the molecular weight of the antibody (specific copolymer / antibody) is not particularly limited, but is preferably 1 / 30 to 1 / 5.

[0047] The polydispersity index (PDI) of the specific copolymer is not particularly limited, but from the viewpoint of obtaining a copolymer having a better effect of the present invention, it is preferably 1.5 or less, and more preferably 1.3 or less.

[0048] (Other units) The specific copolymer may have a repeating unit other than the above. Examples of the repeating units other than the above include repeating units based on N-cyclopropylacrylamide (LCST = 46 ° C), Nn-propylacrylamide (LCST = 22 ° C), N-tetrahydrofurfuryl acrylamide (LCST = 28 ° C), N-ethoxyethylacrylamide (LCST = 35 ° C), N-methyl-N-ethylacrylamide (LCST = 56 ° C), N-methyl-N-isopropylacrylamide (LCST = 23 ° C), N-methyl-Nn-propylacrylamide (LCST = 20 ° C), N,N-diethylacrylamide (LCST = 32 ° C), N-cyclopropylmethacrylamide (LCST = 59 ° C), N-isopropylmethacrylamide (LCST = 44 ° C), Nn-propylmethacrylamide (LCST = 28 ° C), and N-tetrahydrofurfurylmethacrylamide (LCST = 35 ° C).

[0049] [Method of producing specific copolymer] The method for producing the specific copolymer is not particularly limited, but from the viewpoint of more simply producing the specific copolymer, it is preferable to have the following step (1) and step (2) in this order.

[0050] Step (1): A step of copolymerizing monomers represented by the following formula 1' and formula 3' to obtain a copolymer (precursor).

[0051] [ka]

[0052] In the above formulas 1' and 3', X 1 , and X 2 are the X in Eq. 1 and X in formula 2′ 2 The same applies to the preferred embodiments.

[0053] The method for copolymerizing the above monomers is not particularly limited, and it is preferable to use a living polymerization method such as a living radical polymerization method, a living anionic polymerization method, and a living cationic polymerization method. Among them, the living radical polymerization method is preferable from the viewpoint of more easily obtaining a copolymer (precursor).

[0054] Living radical polymerization is based on the establishment of a rapid equilibrium between a small amount of growing radical (free radical) species and a large amount of dormant species in the propagation reaction by the action of heat, light, and metal catalysts, etc. Various forms of living radical polymerization have been proposed based on the dormant chain.

[0055] For example, there are the ATRP method (atom transfer radical polymerization method) that uses an alkyl halide as a dormant, the RAFT method (reversible addition fragmentation chain transfer) that uses a thioester, and the NMP method (nitroxide mediated polymerization method) that uses an alkoxyamine.

[0056] The RAFT method is a method in which a vinyl monomer is polymerized by adding a chain transfer agent with a high chain transfer constant called a RAFT agent to a conventional radical polymerization system. Thioesters can be used as RAFT agents.

[0057] The amount of the RAFT agent can be appropriately selected depending on the molecular weight of the target copolymer. That is, since the RAFT agent is bonded to the terminal of each copolymer, for example, when a 100-mer copolymer is the target, 0.1 to 3 mol % of the RAFT agent may be used relative to 100 mol % of the monomer.

[0058] The radical polymerization initiator used in the RAFT polymerization is not particularly limited, and may be appropriately selected from known initiators such as azo compounds, peroxides, and redox-type initiators.

[0059] Examples of azo compounds include 2,2'-azobisisobutyronitrile (AIBN), 2,2'-azobis2,4-dimethylvaleronitrile, 2,2'-azobis(2-methylpropionamidine) dihydrochloride, and 4,4'-azobis(4-cyanovaleric acid).

[0060] The polymerization initiator is generally used in an amount of 0.1 to 50 mol% per mole of the RAFT agent. The reaction temperature of the RAFT method is determined by the radical polymerization initiator used, but is generally 40°C to 150°C. Polymerization is often carried out under atmospheric pressure, but polymerization under pressure is also possible.

[0061] The RAFT method can be carried out in the absence of a solvent, but can also be carried out in the presence of a solvent. The solvent to be used as necessary is not particularly limited, and any known solvent can be used. The reaction can also be carried out in water, and the reaction can also proceed by emulsion polymerization. The emulsifier used in this case can be a nonionic emulsifier, cationic emulsifier, or anionic emulsifier that can be used in general emulsion polymerization.

[0062] Step (2): A step of reacting the obtained copolymer (precursor) with a precursor compound represented by formula 4' to obtain a specific copolymer.

[0063] [ka]

[0064] In formula 10, Z is a group containing a click reaction site (e.g., a cyclic alkyne), and is preferably a group selected from the groups represented by formula C described above. In formula C, * represents L 10 The bonding position with Also, L 10 represents a divalent group, and L in formula 2 2The same applies to the preferred embodiments.

[0065] The desired specific copolymer is synthesized by forming (condensing) an ester bond between a hydroxy group of the copolymer (precursor) and a carboxy group of the precursor compound represented by formula 4'.

[0066] The method for forming the ester bond is not particularly limited, and examples thereof include a method in which a copolymer (precursor) and a precursor compound are subjected to a condensation reaction in the presence of a condensing agent, a catalyst, and a solvent at 0 to 150°C (preferably 0 to 100°C) for 30 minutes to 24 hours (preferably 3 to 15 hours).

[0067] As the condensation agent, triphenyl phosphite, N,N'-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N,N'-carbonyldiimidazole, dimethoxy-1,3,5-triazinylmethylmorpholinium, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, and (2,3-dihydro-2-thioxo-3-benzoxazolyl)diphenyl phosphonate can be used, among which N,N'-dicyclohexylcarbodiimide is preferred, in which case N,N-dimethyl-4-aminopyridine or the like can be used as the catalyst, and dichloromethane or the like can be used as the solvent.

[0068] (Applications of specific copolymers) Since the specific copolymer has an LCST and a click reaction site, it specifically and irreversibly binds to, for example, a compound having an azide group dispersed or dissolved in a liquid medium containing water to form a complex. When this solution is heated to a temperature equal to or higher than the LCST, the complex rapidly aggregates and precipitates, and can be easily separated from the liquid medium. For example, a complex between a compound having an azide group and an antibody is prepared in advance, and then a conjugate with a specific copolymer is prepared; or a conjugate is prepared by mixing a compound having an azide group, an antibody, and a specific copolymer; and then a corresponding antigen is bound to the complex, and the complex is heated to the LCST or higher, whereby the antigen can be recovered together with the conjugate.

[0069] [Antibody-copolymer conjugates] The antibody-copolymer conjugate according to an embodiment of the present invention is an antibody-copolymer conjugate in which the copolymer already described is bound to an antibody via a linker represented by the following formula 6.

[0070] [ka]

[0071] In formula 6, L 6 represents a divalent hydrocarbon group which may have a heteroatom, and is preferably a (poly)oxyalkylene group (the alkylene group preferably has 1 to 6 carbon atoms) or a linear, branched or cyclic hydrocarbon group having 1 to 20 carbon atoms, more preferably a polyoxyalkylene group. The number of repetitions of the polyoxyalkylene group is preferably 2-10, and more preferably 2-8.

[0072] The linker represented by formula 6 has an N-hydroxysuccinimidyl ester (NHS ester) and can form an amide bond with a primary amine (e.g., a lysine residue) of a protein. That is, it bonds with -NH2 of an antibody to form a complex. On the other hand, the linker has an azide group and bonds with an alkynylene group (click reaction site) of a specific copolymer to form a triazole ring.

[0073] Preferred forms of the antibody-copolymer conjugate include antibody-copolymer conjugates having a repeating unit represented by the following formula 1 and a repeating unit represented by the following formula 7.

[0074] [ka]

[0075] In formula 7, X 2 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms; 2 The same applies to the preferred embodiments. Also, L 2 represents a divalent group, and L in formula 2 2 The same applies to the preferred embodiments. 6 represents a divalent hydrocarbon group which may have a heteroatom; L in formula 6 6 The same applies to the preferred embodiments. Furthermore, Ab represents an antibody residue, that is, an amide bond is formed between the primary amine of the antibody and the NHS ester of the linker, and the antibody is immobilized to a specific copolymer via the linker.

[0076] In the above-mentioned form, the antibody and the unit 7 are bound in a one-to-one ratio; however, the antibody-copolymer conjugate is not limited to the above-mentioned form, and may have a state in which a plurality of primary amines of the antibody are bound to alkynylene groups of the specific copolymer via linkers, i.e., a crosslinked structure centered on the antibody molecule.

[0077] Furthermore, the antibody-copolymer conjugate may contain unit 2 represented by formula 2 in addition to the above repeating units. That is, it may contain unreacted unit 2. In one embodiment, since the molecule of the specific copolymer is smaller than the molecule of the antibody, it may be difficult for a large number of antibodies to bind to the specific copolymer. In this case, the antibody-copolymer conjugate may contain unreacted unit 2 remaining.

[0078] The ratio of the antibody to the specific copolymer is not particularly limited, but in one embodiment, it is preferably 0.1 to 50 moles of the copolymer per mole of the antibody.

[0079] In addition, the antibody-copolymer conjugate may contain other units (unit 5) that the specific copolymer may contain, and the preferred range of the content of each unit is the same as the preferred range for the specific copolymer.

[0080] The antibody is not particularly limited and any known antibody can be used, but among them, an anti-SARS-CoV-2 antibody is preferred, and for example, an anti-SARS-CoV-2 (COVID19) nucleocapsid (protein) antibody and an anti-SARS-CoV-2 spike (protein) antibody are more preferred. In this case, the molar content ratio of the specific copolymer content to the antibody content in the antibody-copolymer conjugate is not particularly limited, but is preferably 0.5 to 30.

[0081] [Antigen concentration method] A method for concentrating an antigen according to an embodiment of the present invention includes preparing a mixed solution A containing the above-mentioned antibody-specific copolymer conjugate and an antigen, forming a complex between the antibody-specific copolymer conjugate and the antigen, and heating the mixed solution A to 20 to 40°C to precipitate the complex.

[0082] Mixture A can be prepared, for example, by adding an antibody-specific copolymer conjugate to a specimen obtained by diluting or dispersing saliva, sputum, etc. collected from a subject with a liquid medium (e.g., phosphate-buffered saline, etc.) as necessary.

[0083] The mixed solution A only needs to contain the antibody-specific copolymer conjugate and the antigen. The antibody-copolymer conjugate may be prepared in advance and the antigen may be added thereto, or the antigen may be added to a solution in which the specific copolymer, the linker, and the antibody are mixed, or the specific copolymer, the linker, the antibody, and the antigen may be mixed at once.

[0084] The amount of antibody-specific copolymer conjugate added to a specimen is not particularly limited, but there is a correlation between the amount added and the concentration rate, and for example, the amount of specific copolymer added to 1 mg of antigen protein in a specimen is preferably 0.1 mg or more, more preferably 0.5 mg or more, and even more preferably 1.0 mg or more. The upper limit is not particularly limited, but generally, 5.0 mg or less is preferred. More specifically, the amount of the specific copolymer added is preferably 0.1 to 10.0 mg per 1 mL of sample liquid (including, for example, saliva).

[0085] At this time, a specific copolymer in a free state (one that has not formed a conjugate with the antibody) may be further added to the mixed solution A. The addition of the specific copolymer makes the response to heat more sensitive, and allows the antigen to be concentrated more efficiently. The amount of the specific copolymer added is not particularly limited, but is preferably 0.1 to 20 times the molar content of the copolymer contained in the antibody-copolymer conjugate, which is taken as 1.

[0086] Furthermore, the method for concentrating an antigen preferably includes the steps of: binding the linker already described to an antibody via an amide bond derived from an amino group in the antibody to prepare an antibody-linker conjugate; preparing a mixed solution B containing the antibody-linker conjugate and a specific copolymer; and reacting an azide group in the antibody-linker conjugate with an alkynylene group in the copolymer in mixed solution B to bind them together, thereby producing an antibody-specific copolymer conjugate.

[0087] The antigen that can be concentrated by this method is not particularly limited and can be appropriately selected depending on the type of antibody possessed by the antibody-copolymer conjugate. Among them, the antigen is preferably a SARS-CoV-2 protein, more preferably a SARS-CoV-2 spike protein, a SARS-CoV-2 nucleocapsid protein, etc.

[0088] [kit] The kit for preparing an antibody-specific copolymer conjugate according to the embodiment of the present invention includes the copolymer and a linker described above. The kit only needs to include the specific copolymer and the linker, and may further include a solvent and the like. Alternatively, the specific copolymer may be added in advance to the developing solution of an antigen test kit for immunochromatography. In this case, the specific copolymer and the linker may be in a state of being bonded in advance in the developing solution (solution).

[0089] [Antigen test kit] The antigen test kit according to the embodiment of the present invention is an antigen test kit including the specific copolymer and a linker described above. The antigen test kit may include a known antigen test device in addition to the above. The specific configuration of the antigen test device is not particularly limited, but it is preferable that the antigen test device is used for testing by an immunological method. For example, the antigen test device may be a test strip generally used for testing by an immunochromatography method, or may be a device having another configuration.

[0090] The specific configuration of the antigen test kit is not particularly limited. For example, the specific copolymer, the linker, and the antigen test device may be in a separate state, or the specific copolymer, the linker, and the antigen test device may be in an integrated state. EXAMPLES

[0091] The present invention will be described below with reference to examples, but the present invention is not limited to these.

[0092] [Synthesis of HIPAAm] HIPAAm (Hydroxy IsoPropyl AcrylAmide) was synthesized according to the following procedure: D,L-2-amino-1-propanol (0.15 mol) and triethylamine (0.15 mol) were thoroughly dissolved in anhydrous chloroform and stirred at 5°C for 20 minutes, after which acryloyl chloride (0.15 mol) was slowly added and stirred at 5°C for 2 hours.

[0093] After evaporating the solvent, the mixture was redissolved in 2-propanol and kept at -20°C for more than 24 hours. Finally, it was filtered to remove salts, and concentrated and purified by column chromatography. The synthesis of HIPAAm was confirmed by thin layer chromatography (TLC) and 1 The reaction was confirmed by H NMR (Nuclear Magnetic Resonance) (solvent: D2O).

[0094] [ka]

[0095] [Synthesis of P(NIPAAm-co-HIPAAm)] P(NIPAAm-co-HIPAAm) was synthesized by RAFT polymerization of HIPAAm and NIPAAm as shown in the following scheme: A solution containing 1.89 g of NIPAAm, 0.11 g of HIPAAm, 1.31 mg of AIBN, 12.7 mg of CDT (cyanomethyl dodecyl trithiocarbonate), and 17.6 ml of ethanol was stirred at 20°C for 20 hours, evaporated, and dried in vacuum.

[0096] [ka]

[0097] [Synthesis of P(NIPAAm-co-HIPAAm-co-SAKIPAAm)] As shown in the scheme below, dibenzylcyclooctynoic acid (DBCO) having an alkynylene group was introduced to the hydroxyl group of HIPAAm by dehydration condensation to obtain a clickable responsive polymer P (NIPAAm-co-HIPAAm-co-SAKIPAAm). A solution containing 30 ml of DCM (dichloromethane), 35.8 mg of DBCO acid, 12 mg of DMAP (4-dimethylaminopyridine), 100 mg of P (NIPAAm-co-HIPAAm), and 20 mg of DCC (N',N'-dicyclohexylcarbodiimide) was stirred overnight, evaporated, and dried in vacuum. The resulting P (NIPAAm-co-HIPAAm-co-SAKIPAAm) is hereinafter also referred to as "copolymer (I)".

[0098] [ka]

[0099] [Evaluation of polymer synthesis] Both P(NIPAAm-co-HIPAAm) and copolymer (I) have the following structures: 1 The molecular weight was confirmed by H NMR (solvent: DO, DMSO) and gel permeation chromatography (GPC) (solvent: DMF (N,N-Dimethylformamide), standard substance: polystyrene). The lower critical solution temperature (LCST) was confirmed using phosphate buffered saline (PBS) (pH: 7.4, concentration: 2.0 mg / mL, temperature: 10 to 40°C) as the solvent.

[0100] [Introduction of azide groups into antibodies] Azido-PEG4-NHS ester (Azido-ethylene glycol (EG4)-NHS ester, Tokyo Chemical Industry Co., Ltd.) powder was dissolved in DMSO (10 mg / ml) and carbonate buffer (PH 8.6) was used to prepare azide-PEG4-NHS ester at different concentrations. The azide-PEG4-NHS ester was added to the antibody (anti-COVID-19 monoclonal antibody, >95%, MyBioSource, anti-COVID-19 antibody :: anti-Viral COVID 19 Nucleocapsid (NP) Humanized Coronavirus Monoclonal Antibody) at different supply ratios, and then stirred at 4°C for 5 hours to introduce azide groups into the antibody, as shown in the formula below.

[0101] [ka]

[0102] After the introduction of azide groups into the antibodies, the fluorescence of the antibody samples was measured using an “Infinite” 200 PRO plate reader as follows: The azide-modified antibody samples were diluted to 0.5 mg / ml and applied to a 96-microwell plate containing different concentrations of DL-2-aminobutyric acid (50 μL / well, standard), then 5 μL of fluorescamine (50 mg / ml) was added to each well, incubated for 15 min in the dark, and the fluorescence was measured (395 nm / 495 nm).

[0103] [Preparation of COVID-19 antibody-temperature-responsive copolymer conjugates via click reaction] Using click chemistry, the azide-modified antibody was conjugated to the alkynylene group-modified temperature-responsive copolymer as follows: 75 μl of copolymer (I) was mixed with 50 μl of azide-modified anti-COVID 19 antibody (2.5 mg / mL in PBS) and stirred at 4 °C for 12 h as shown in the following scheme:

[0104] The concentration of copolymer (I) was adjusted to give antibody to copolymer (I) ratios of 1:1, 1:2, 1:4, 1:8, 1:15, and 1:30 (all on a molar basis). Successful conjugates were characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in comparison with the antibody and copolymer (I) alone.

[0105] [ka]

[0106] [Evaluation of the concentration effect of COVID-19 antibody-temperature-responsive copolymer] The concentration effect of the previously prepared COVID-19 antibody-copolymer conjugate (1:1) was evaluated by thermal precipitation. The purified COVID-19-copolymer conjugate (containing 15 equivalents of a specific free copolymer in 100 μL of PBS solution at a concentration of 1.3 mg / mL) was added to a microtube and centrifuged (13,000 × g) at 37 °C for 5 minutes. The supernatant (90 μL) and precipitate (10 μL) were then collected, and the absorbance at 280 nm was measured using a UV-Vis spectrophotometer. The molar ratio of COVID-19 antibodies in the liquid phase and solid phase was estimated, and the concentration rate was calculated.

[0107] [Evaluation of antigen concentration effect of COVID-19 antibody-temperature responsive copolymer] The enrichment ability of COVID-19 recombinant protein (MyBioSource) was evaluated against purified COVID-19 antibody-copolymer conjugates (1.3, 0.7, 0.35, 0.17, 0.08, 0 mg / mL, 50 μL PBS, containing 15 equivalents of copolymer (I) alone).

[0108] COVID-19 antibody-copolymer conjugates (different concentrations, 50 μL PBS) were mixed with COVID-19 recombinant protein (1.0 mg / mL, 50 μL PBS) and incubated for 1 h, after which the free polymer was added to the solution and centrifuged at 13,000 × g for 5 min at 37 °C in a microtube. The supernatant (90 μL) and precipitate (10 μL) were collected, and the COVID-19 recombinant protein in the supernatant was measured using a modified lowery protein assay kit according to the manufacturer's instructions, and finally the concentration rate was calculated.

[0109] [Evaluation of the antigen concentration effect of COVID-19 antibody-temperature responsive copolymer using lateral flow immunoassay strips] Different concentrations of COVID-19 recombinant protein (50-1000 pg / mL, 20 μL PBS) were tested using lateral flow immunoassay strips. COVID-19 recombinant protein (50, 100 pg / mL, 100 μL PBS) was mixed with COVID-19 antibody-specific copolymer conjugate (1.3 mg / mL, 100 μL PBS) and incubated for 1 h, after which 15 equivalents of free polymer [copolymer (I)] was added and centrifuged at 37 °C, 13,000 × g, 5 min in a microtube. The supernatant (180 μL) and precipitate (20 μL) were collected, and the concentrated portion was measured by LFIA.

[0110] [result] (Confirmation of HIPAAm synthesis) The purification of the HIPAAm monomer was confirmed by TLC analysis. In the image in Figure 1, "(1)" is a HIPAAm standard sample, and "(2)" is the synthesized sample before and after column purification. (Stationary phase: silica gel plate, mobile phase: ethyl acetate, visualization agent: KMnO4 solution)

[0111] According to Figure 1, HIPAAm was successfully prepared with two major secondary products. As shown in Figure 1, column chromatography was used for the purification of HIPAAm, and finally 1 The H NMR results were used to confirm the synthesis of HIPAAm (Figure 2).

[0112] (Identification and Characterization of P(NIPAAm-co-HIPAAm) and Copolymer (I)) 1As a result of H NMR analysis, we confirmed that by polymerizing HIPAAm and NIPAAm in a ratio of 3.6:96.4 (molar basis), we succeeded in raising the LCST of P(NIPAAm), which is known to be approximately 32 °C, to 37.4 °C by introducing the hydroxyl group of HIPAAm, and that by combining the SAK group, a strained alkyne, we formed a temperature-responsive copolymer (I) in a ratio of 96.4:1.2:2.4 (molar basis) (Figures 3 and 4).

[0113] As for the molecular weight, the results of GPC analysis showed that the molecular weight of the synthesized polymer was 1.904 × 10 by inserting the SAK group, as shown in Figures 3 to 7 and Table 1. 4 to 2.014 × 10 4 It was found that it had changed to.

[0114] FIG. 5 shows the measurement results of the LCST of P(NIPAAm-co-HIPAAm), FIG. 6 shows the results of the LCST of copolymer (I), and FIG. 7 shows the results of the LCST of the antibody-copolymer (I) conjugate. The measurements were performed using PBS (pH 7.4) as the solvent, a copolymer concentration of 2.0 mg / mL, a heating rate of 0.2°C / min, and a wavelength of 450 nm. The LCST was defined as the temperature at which the light transmittance reached 50%. From this, it was found that the LCST changed from 37.4°C for P(NIPAAm-co-HIPAAm) to 30.1°C for copolymer (I).

[0115] [Table 1]

[0116] (Synthesis of azido-COVID-19 antibody) Azide groups were introduced into COVID-19 antibodies by binding azido-(EG)4-NHS to the lysine residues (ε-amino groups) of the antibodies. Azide-(EG)4-NHS was confirmed and quantified using a fluorescent reduction method. With increasing amounts of azido-(EG)4-NHS added, the amount of azide groups bound gradually increased (0, 6.7, 10.7, 20.9 mol / mol) as shown in Figure 8, while the amount of amine groups bound gradually decreased (21.1, 14.7, 10.7, 0.2 mol / mol). p-value<0.0001.

[0117] In addition, we attempted to synthesize azide-COVID-19 antibodies in the same manner, except that we used "SARS-CoV-2 Spike Protein (S1-NTD) Antibody #56996" (Cell Signaling Technology) instead of anti-COVID-19 monoclonal antibody (>95%, MyBioSource, anti-COVID-19 antibody :: anti-Viral COVID 19 Nucleocapsid (NP) Humanized Coronavirus Monoclonal Antibody), and the synthesis was similarly successful. Figure 14 shows the results, and as the amount of azide (EG)4-NHS added was increased, the amount of azide group bound gradually increased and the amount of amine group bound gradually decreased.

[0118] (Confirmation of Anti-COVID-19 Copolymer (I) Conjugate Synthesized by Click Reaction) FIG. 9 is a gel image of COVID-19 antibody-copolymer (I) conjugate by sodium dodecyl sulfate gel electrophoresis (SDS-PAGE).

[0119] Here, (1) and (11) are protein ladders, (2) is antibody:copolymer (I) at 1:1 (mol / mol), (3) is 1:2, (4) is 1:4, (5) is 1:8, (6) is 1:15, (7) is 1:30, (8) is copolymer (I) itself, (9) is an azide-antibody, and (10) is an antibody.

[0120] When the ratio of COVID-19 antibody to copolymer (I) was changed to 1:1, 1:2, 1:4, 1:8, 1:15, and 1:30 (lanes 2 to 7), increasing the amount of copolymer in the reaction solution increased the binding with the antibody, ultimately broadening the band and increasing the molecular weight of the conjugate. These results demonstrate the successful synthesis of COVID-19 antibody-specific copolymer conjugates.

[0121] (Evaluation of the concentration effect of COVID-19 antibody-temperature-responsive copolymer) The COVID-19 antibody-temperature responsive copolymer showed highly significant enrichment ability after thermal precipitation compared to the control (p=0.0006).

[0122] (COVID-19 antibody-antigen enrichment using temperature-responsive copolymer) As shown in Figure 10, increasing the concentration of COVID-19 antibody-copolymer conjugates shifted the fold number of COVID-19 recombinant protein from 0 to about 6 times the original antigen concentration at the highest concentration of conjugate (1.3 mg / mL), indicating the ability of the developed system to enrich samples with low viral load (p<0.05). Note that the unit of the horizontal axis in Figure 10 is mg / mL.

[0123] (Evaluation of antigen concentration using lateral flow immunoassay strips) As shown in Figure 11, the minimum detection limit of COVID-19 recombinant protein using LFIA was approximately 50 pg / mL (a5), and it showed a weak faint band in the test zone at 100 pg / mL (a4), but showed a strong positive band at concentrations from 200 to 1000 pg / mL, respectively, as shown in Figure 11 (a1), (a2), and (a3).

[0124] Figure 12 shows a comparison before and after concentration: (b1) 50 pg / mL without concentration, (b2) 50 pg / mL after concentration, (b3) 100 pg / mL without concentration, and (b4) 100 pg / mL after concentration. It was found that concentration using the COVID-19 antibody-copolymer conjugate showed a strong positive band (indicated by a triangle in the figure).

[0125] [Synthesis of P(NIPAAm-co-HIPAAm-co-SAKIPAAm)2] In the synthesis of P(NIPAAm-co-HIPAAm-co-SAKIPAAm), the amount of NIPAAm added was changed from 1.89 g to 1.6 g, and the amount of HIPAAm added was changed from 0.1 g to 0.0034 g, but in the same manner as above, P(NIPAAm-co-HIPAAm-co-SAKIPAAm) was synthesized. Hereinafter, the synthesized copolymer will be referred to as "copolymer (II)". The molecular weight of copolymer (II) is 1.82 × 10 4 The amount of SAKIPAAm introduced was 14 mol % when the total amount of repeating units was 100 mol %.

[0126] [Table 2]

[0127] Fig. 13 shows the measurement results of the LCST of the synthesized copolymer (II), which was found to be 29.1°C. From the above results, it was found that when the total repeating units are taken as 100 mol %, copolymer (II) having a content of SAKIPAAm units (corresponding to units represented by general formula 2) having a click reaction site of 5 to 30 mol % or less can perform antigen concentration at a lower temperature than copolymer (I). [Industrial Applicability]

[0128] As shown above, this copolymer can dramatically reduce the false positive rate caused by the small amount of target substance (antigen, etc.) in the sample, and can improve the accuracy of the test. In particular, the use of an antibody-copolymer conjugate with SARS-CoV-2 antibody immobilized thereon can dramatically improve the accuracy of the SARS-CoV-2 test.

Claims

1. A copolymer comprising unit 1, which is a repeating unit represented by the following formula 1, and unit 2, which is a repeating unit represented by the following formula 2-1. 【Chemistry 1】 (In formula 1, X 1 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms. 【Chemistry 2】 (In formula 2-1, X 2 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms, and L 22 represents a divalent group, and as a monovalent group bonded at the position * after the wavy line, has a structure selected from the following formula C. 【Chemistry 3】

2. 2. The copolymer according to claim 1, wherein the content of the unit 2 is 1.0 to 30.0 mol % when all repeating units are taken as 100 mol %.

3. The copolymer according to claim 1 or 2, wherein the unit 2 is a unit 3 represented by the following formula 3 or a unit 4 represented by the following formula 4: 【Chemistry 4】 (In Formula 3 and Formula 4, X 2 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms; 3 is -O-, -S-, and -NR 2 -, R 2 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, n represents an integer of 1 to 10, and in formula 4, L 23 represents a divalent group.

4. The copolymer according to any one of claims 1 to 3, further comprising a repeating unit represented by the following formula 5: 【Chemistry 5】 (In formula 5, X 5 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms.

5. The copolymer according to any one of claims 1 to 4, wherein the content of the unit 2 is 5 to 30 mol % or less when the total amount of all repeating units is taken as 100 mol %.

6. The copolymer according to any one of claims 1 to 5, having a number average molecular weight of 5,000 to 50,000.

7. A kit for producing an antibody-copolymer conjugate, comprising the copolymer according to any one of claims 1 to 6 and a linker represented by the following formula 6: 【Chemistry 6】 (In formula 6, L 6 represents a divalent hydrocarbon group which may have a heteroatom.

8. An antibody-copolymer conjugate having unit 1, which is a repeating unit represented by the following formula 1, and unit 7, which is a repeating unit represented by the following formula 7: 【Chemistry 7】 (In formula 1, X 1 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms; 2 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms; L 23 represents a divalent group; L 6 represents a divalent hydrocarbon group which may have a heteroatom, and Ab represents a residue of an antibody protein.

9. The antibody-copolymer conjugate of claim 8, wherein said Ab is an anti-SARS-CoV-2 antibody.

10. preparing a mixture A containing the antibody-copolymer conjugate according to claim 8 or 9 and an antigen corresponding to the antibody, and forming a complex between the antibody-copolymer conjugate and the antigen; and heating the mixture A to 20 to 40°C to precipitate the complex.

11. A method for producing an antibody-linker conjugate by binding a linker represented by the following formula 6 to an antibody via an amide bond derived from an amino group of the antibody: preparing a mixed solution B containing the antibody-linker conjugate and a copolymer including unit 1, which is a repeating unit represented by the following formula 1, and unit 2, which is a repeating unit represented by the following formula 2-1; reacting an azide group of the antibody-linker complex with an alkynylene group of the copolymer in the mixture B to bond them together, thereby producing an antibody-copolymer conjugate; preparing a mixture A containing an antibody-copolymer conjugate and an antigen corresponding to the antibody, and forming a complex between the antibody-copolymer conjugate and the antigen; and heating the mixture A to 20° C. or higher to precipitate the complex. 【Chemistry 8】 (In formula 1, X 1 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms. 【Chemistry 9】 (In formula 2-1, X 2 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms, and L 22 represents a divalent group, and as a monovalent group bonded at the position * after the wavy line, has a structure selected from the following formula C. 【Chemistry 10】 【Chemistry 11】 (In formula 6, L 6 represents a divalent hydrocarbon group which may have a heteroatom.

12. The method for concentrating an antigen according to claim 10 or 11, wherein the antibody is an anti-SARS-CoV-2 antibody.

13. The method for concentrating an antigen according to claim 12, wherein the antigen is a SARS-CoV-2 protein.

14. The method for concentrating an antigen according to claim 11, wherein a molar ratio of a content of the copolymer to a content of the antibody contained in the antibody-linker complex in the mixed solution B is 0.5 to 30.

15. A method for detecting an antigen, comprising: concentrating an antigen by the method for concentrating an antigen according to any one of claims 10 to 14; and detecting the concentrated antigen.

Citation Information

Patent Citations

  • Isopropyl acrylamide derivative having azido group or alkyne group and polymer thereof

    JP2012201634A

  • Polymer adjuvant

    US20170304420A1

  • Photosensitive composition, patterned substrate, cell culture support, and cultured cell production method

    WO2016068271A1